Y-mAbs Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Y-mAbs Therapeutics

09/08/2022 02:39

* Y-mAbs Therapeutics Inc  YMAB.OQ  reported a quarterly
adjusted
loss of 94 cents​​ per share for the quarter ended in June. The
mean expectation of nine analysts for the quarter was for a loss
of 67 cents per share.
    * Revenue fell 1.4% to $10.80 million from a year ago;
analysts
expected $11.22 million. 
    * Y-mAbs Therapeutics Inc's reported EPS for the quarter was
a
loss of 94 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Y-mAbs Therapeutics Inc shares had risen by 25.3% this
quarter and gained 17.0% so far this year.
    * The company reported a quarterly loss of $41.13 million.
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $25.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 01:39 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.67          -0.94          Missed
 Mar. 31 2022      -0.72          -0.64          Beat
 Dec. 31 2021      -0.70          -0.85          Missed
 Sep. 30 2021      -0.60          -0.66          Missed